Bionure

bionure is a biotech company developing therapies for the treatment of of rare, ophthalmological diseases for which no treatment options are nowadays available. we focus in particular in two conditions in which patients suffer from vision impairment and blindness, paralysis and even death: acute optic neuritis and neuromyelitis optica. our lead candidate bn201 is a small molecule, new chemical entity, first-in-class drug at ind-stage that has been shown to promote neuroprotection and remyelination in several animal models of damage. bn201 has been granted orphan designation for acute optic neuritis in europe and the us and we have reached an agreement with fda on study design and primary endpoints, which makes the clinical program feasible and affordable. with these patients in mind, we have built an extraordinary committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of th